Tata India Pharma & Healthcare Fund Direct Growth

Equity
Direct
Sector - Healthcare
Tata India Pharma & Healthcare Fund Direct Growth

About the Fund

Tata India Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on 28 December, 2015. The fund is managed by Meeta Shetty. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. Tata India Pharma & Healthcare Fund Direct Growth has ₹899 Cr worth of assets under management (AUM) as on May 2024 and is less than category average.
  2. The fund has an expense ratio 0.8.

Returns

Tata India Pharma & Healthcare Fund Direct Growth has given a CAGR return of 13.82% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 49.63%, 18.05% and 27.05% respectively.

Holdings

Tata India Pharma & Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Aurobindo Pharma Ltd, Lupin Ltd, Dr Reddy's Laboratories Ltd, Cipla Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of Tata India Pharma & Healthcare Fund Direct Growth

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. Tata India Pharma & Healthcare Fund Direct Growth has no lock in period.

Fund Performance
zero opening, trading, fund transfer fee
1888 people have invested ₹ 81.8L in Tata India Pharma & Healthcare Fund Direct Growth in the last three months

INDmoney Rank

Powered by IND quant engine
IND ranking is not available for this fund.
img
3Y returns in the top 25% of the category
img
Beats FD returns for both 3Y & 5Y duration
img
No bad points found for this fund.

Fund Overview

Expense ratio0.83%
Benchmark
S&P BSE Healthcare PR
AUM₹899 Cr
Inception Date28 December, 2015
Min Lumpsum/SIP₹5000/₹100
Exit Load
0.25%
Lock InNo Lock-in
TurnOver
23.3%
Risk
Risk meter
pointer
Very High Risk

Fund Distribution
as on (31-May-24)

  • Equity 96.9%

  • Debt & Cash 3.1%

Mid cap
39.7%

Large cap
38.6%

Small cap
18.6%

Sector Allocation

May'24

Apr'24

Mar'24

Health
98%
Basic Materials
2%
All changes are between Mar'24 and May'24

Returns for the month of May

  • Gainers

  • Losers

Meeta Shetty
Meeta Shetty
Fund Manager of Tata India Pharma & Healthcare Fund Direct Growth, since 9 March 2021

Mutual Fund Insights

Insights icon
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.83% which is lower than the category average expense ratio of 1.43%.
Insights icon
In the last 5 years, DSP Healthcare Fund Direct Growth has given 29.68% return, outperforming this fund by 2.63% per annum.
Insights icon
In the last 3 years, this fund has outperformed all funds in its category.
Insights icon
Over the last 1 year, this fund has decreased expense ratio by 17.0% moving from 1.00 to 0.83.
Insights icon
In the last 1 year, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 52.88% return, outperforming this fund by 3.25%.

Tata India Pharma & Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 13.82% since inception which is less than its category average return of 21.09%
Fund Allocations

Fund Allocations

This fund has an allocation of 96.91% in Equity, 0% in Debt and 3.09% in Cash related instruments
AUM size ₹899 Cr

AUM size ₹899 Cr

This fund has AUM of ₹899 Cr which is less than its category average of ₹ 1665 Cr
Expense Ratio 0.83%

Expense Ratio 0.83%

This fund has an expense ratio of 0.83% which is less than its category average expense ratio of 1.45%

Frequently Asked Questions

The current NAV of Tata India Pharma & Healthcare Fund Direct Growth is ₹29.94 as on 21-Jun-2024.
Existing (Absolute + CAGR) as on 21-Jun-2024.
Tata India Pharma & Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
3%
3%
6 Month Returns
21.84%
21.84%
1 Year Returns
49.63%
49.63%
3 Years Returns
64.51%
18.05%
5 Years Returns
230.98%
27.05%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.83% as on May 2024
₹899 Cr as on May 2024
Sun Pharmaceuticals Industries Ltd(13.06%), Aurobindo Pharma Ltd(9.77%), Lupin Ltd(8.98%), Dr Reddy's Laboratories Ltd(6.93%), Cipla Ltd(6.68%) as on May 2024
The alpha ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
Tata India Pharma & Healthcare Fund Direct Growth
2.84
5.32
8.5
As on May 2024
The alpha for Tata India Pharma & Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
Tata India Pharma & Healthcare Fund Direct Growth
0.92
0.9
0.76
As on May 2024
The Beta for Tata India Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
Tata India Pharma & Healthcare Fund Direct Growth
2.28
0.77
1.13
As on May 2024
The sharpe ratio for Tata India Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
Tata India Pharma & Healthcare Fund Direct Growth
15.48
14.24
16.83
As on May 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.38 as on May 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 1.14 as on May 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Meeta Shetty is the fund manager of Tata India Pharma & Healthcare Fund Direct Growth
The Exit load of Tata India Pharma & Healthcare Fund Direct Growth is 0.25%